Literature DB >> 24467243

Phenotypic screening and fragment-based approaches to the discovery of small-molecule bromodomain ligands.

Laura E Jennings1, Angelina R Measures, Brian G Wilson, Stuart J Conway.   

Abstract

Bromodomains are protein modules that bind to acetylated lysine residues and hence facilitate protein-protein interactions. These bromodomain-mediated interactions often play key roles in transcriptional regulation and their dysfunction is implicated in a large number of diseases. The discovery of potent and selective small-molecule bromodomain and extra C-terminal domain bromodomain ligands, which show promising results for the treatment of cancers and atherosclerosis, has promoted intense interest in this area. Here we describe the progress that has been made to date in the discovery of small-molecule bromodomain ligands, with particular emphasis on the roles played by phenotypic screening and fragment-based approaches. In considering the future of the field we discuss the prospects for development of molecular probes and drugs for the non-bromodomain and extra C-terminal domain bromodomains.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24467243     DOI: 10.4155/fmc.13.197

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  7 in total

1.  Discovery and lead identification of quinazoline-based BRD4 inhibitors.

Authors:  Shyh-Ming Yang; Daniel J Urban; Makoto Yoshioka; Jeffrey W Strovel; Steven Fletcher; Amy Q Wang; Xin Xu; Pranav Shah; Xin Hu; Matthew D Hall; Ajit Jadhav; David J Maloney
Journal:  Bioorg Med Chem Lett       Date:  2018-08-31       Impact factor: 2.823

2.  Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.

Authors:  Natalie H Theodoulou; Paul Bamborough; Andrew J Bannister; Isabelle Becher; Rino A Bit; Ka Hing Che; Chun-wa Chung; Antje Dittmann; Gerard Drewes; David H Drewry; Laurie Gordon; Paola Grandi; Melanie Leveridge; Matthew Lindon; Anne-Marie Michon; Judit Molnar; Samuel C Robson; Nicholas C O Tomkinson; Tony Kouzarides; Rab K Prinjha; Philip G Humphreys
Journal:  J Med Chem       Date:  2015-04-30       Impact factor: 7.446

3.  Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.

Authors:  Shyh-Ming Yang; Makoto Yoshioka; Jeffrey W Strovel; Daniel J Urban; Xin Hu; Matthew D Hall; Ajit Jadhav; David J Maloney
Journal:  Bioorg Med Chem Lett       Date:  2019-03-12       Impact factor: 2.823

Review 4.  Histone Modifications and Cancer.

Authors:  James E Audia; Robert M Campbell
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-04-01       Impact factor: 10.005

5.  Zap-Pano: a Photocaged Prodrug of the KDAC Inhibitor Panobinostat.

Authors:  Kathrin S Troelsen; Ewen D D Calder; Anna Skwarska; Deborah Sneddon; Ester M Hammond; Stuart J Conway
Journal:  ChemMedChem       Date:  2021-07-29       Impact factor: 3.540

Review 6.  Selectivity on-target of bromodomain chemical probes by structure-guided medicinal chemistry and chemical biology.

Authors:  Carles Galdeano; Alessio Ciulli
Journal:  Future Med Chem       Date:  2016-05-19       Impact factor: 3.808

7.  Controlling Intramolecular Interactions in the Design of Selective, High-Affinity Ligands for the CREBBP Bromodomain.

Authors:  Michael Brand; James Clayton; Mustafa Moroglu; Matthias Schiedel; Sarah Picaud; Joseph P Bluck; Anna Skwarska; Hannah Bolland; Anthony K N Chan; Corentine M C Laurin; Amy R Scorah; Larissa See; Timothy P C Rooney; Katrina H Andrews; Oleg Fedorov; Gabriella Perell; Prakriti Kalra; Kayla B Vinh; Wilian A Cortopassi; Pascal Heitel; Kirsten E Christensen; Richard I Cooper; Robert S Paton; William C K Pomerantz; Philip C Biggin; Ester M Hammond; Panagis Filippakopoulos; Stuart J Conway
Journal:  J Med Chem       Date:  2021-07-13       Impact factor: 7.446

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.